American Journal of Ophthalmology最新文献

{"title":"Reply to the Comment on Scleral Thickness in Simple Versus Complex Central Serous Chorioretinopathy.","authors":"Naoya Imanaga, Hideki Koizumi","doi":"10.1016/j.ajo.2024.11.002","DOIUrl":"10.1016/j.ajo.2024.11.002","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of 7 artificial intelligence based intraocular lens power calculation formulas in extremely long Caucasian eyes: Short title: AI-based IOL calculation in extra-long eyes.","authors":"Wiktor Stopyra, Oleksiy Voytsekhivskyy, Andrzej Grzybowski","doi":"10.1016/j.ajo.2024.10.033","DOIUrl":"https://doi.org/10.1016/j.ajo.2024.10.033","url":null,"abstract":"<p><strong>Purpose: </strong>To compare 7 AI-based IOL power calculation formulas in extremely long eyes DESIGN: : Retrospective accuracy and validity analysis.</p><p><strong>Methods: </strong>SETTING: Kyiv Clinical Ophthalmology Hospital Eye Microsurgery Center, Ukraine STUDY POPULATION: : Patients with highly myopic eyes, who underwent uneventful phacoemulsification OBSERVATION PROCEDURES: Prior to cataract surgery IOL power was calculated. The power of the implanted IOL was randomly selected from the outcomes of SRK/T, Holladay 2 or Barrett Universal II. Three months after phacoemulsification, refraction was measured. Post-surgery IOL power calculations were performed utilizing the following formulas: Hill-RBF 3.0, Kane, PEARL-DGS, Ladas Super Formula AI (LSF AI), Hoffer QST, Karmona and Zhu-Lu.</p><p><strong>Main outcome measures: </strong>root mean square absolute error (RMSAE), median absolute error (MedAE) and percentage of eyes with prediction error (PE) within ±0.50 D RESULTS: : Forty eight eyes with axial length exceeding 30.00 mm were studied. Hill-RBF 3.0 yielded the lowest RMSAE (0.788) with statistical superiority only over Karmona (0.956, p=0.021). In terms of MedAE, outcomes obtained by Hoffer QST (0.442) and Hill-RBF (0.490) were statistically significant vs LSF AI (0.800, p=0.013, p=0.008, respectively). The highest percentage of eyes with PE within ±0.50 D was achieved by Hill-RBF 3.0, Kane and Hoffer QST (54.17% each) statistically significant as follows: both Hill-RBF and Kane vs LSF AI (27.08%) and Karmona (39.58%), and Hoffer QST vs LSF AI.</p><p><strong>Conclusion: </strong>All tested formulas demonstrated comparable trueness, with Hill-RBF 3.0 being more accurate than Karmona (RMSAE), and LSF AI being less accurate than Hoffer QST and Hill-RBF 3.0 (MedAE).</p>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142611997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Humanistic Burden of Noninfectious Uveitis: A Systematic Review and Meta-Analysis","authors":"Aswen Sriranganathan ,&nbsp;Justin Grad ,&nbsp;Rafael N. Miranda ,&nbsp;Jobanpreet Dhillon ,&nbsp;Solin Saleh ,&nbsp;Tina Felfeli","doi":"10.1016/j.ajo.2024.10.027","DOIUrl":"10.1016/j.ajo.2024.10.027","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aimed to evaluate the humanistic burden of noninfectious uveitis (NIU).</div></div><div><h3>Design</h3><div>Systematic review and meta-analysis.</div></div><div><h3>Methods</h3><div>A comprehensive search was conducted across Medline, Embase, and Scopus databases from inception to March 2023. Studies pertaining to the health-related quality of life (HRQoL) of patients with NIU in both adult and pediatric populations were included. Identified studies were critically appraised and assessed for bias using the Joanna Briggs Institute Critical Appraisal tools.</div></div><div><h3>Results</h3><div>A total of 68 studies involving 8403 participants met the inclusion criteria, and 10 studies were included in the meta-analysis. Across 14 HRQoL instruments used across the studies, Visual Function Questionnaire 25 was the most frequently used (<em>n</em> = 35), followed by the 36-Item Short-Form Survey and 8-Item Short Form Survey (<em>n</em> = 30), EuroQol 5-Dimensions (<em>n</em> = 8) and Pediatric QoL (<em>n</em> = 8). Thirteen studies assessed pediatric populations (19%), 12 studies compared NIU and systemic disease (18%), 14 studies assessed QoL outcomes with different treatment modalities (21%), and 4 studies explored QoL outcomes through qualitative exploratory methods (6%). Patients with juvenile idiopathic arthritis-associated uveitis had poorer HRQoL scores than nonuveitic juvenile idiopathic arthritis by 5.26 (95% confidence interval [CI] –7.24, –3.28; <em>P</em> &lt; .05) on the Effects of Youngsters’ Eyesight on QoL questionnaire and the Childhood Health Assessment Questionnaire. Adults with NIU with systemic disease scored notably lower on both Mental Component Summary (mean difference: –5.63; 95% CI –9.37, –1.88; <em>P</em> &lt; .01) and Physical Component Summary (mean difference: –4.99; 95% CI –11.71, 1.73; <em>P</em> &lt; .01) segments of the 36-Item Short-Form Survey compared to healthy controls. Overall, the studies were of moderate to high quality.</div></div><div><h3>Conclusions</h3><div>NIU poses a significant QoL impact from a physical health, mental health, daily functioning, and caregiving perspective. Patients with NIU experience significant declines in QoL, particularly those with comorbid conditions and systemic diseases, highlighting the need for validation of uveitis-specific patient-reported outcome measures. Future studies should develop interventions and explore QoL impacts on diverse geographic regions.</div></div>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"271 ","pages":"Pages 43-59"},"PeriodicalIF":4.1,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Comment on Ophthalmic Immune-Related Adverse Events and Association With Survival: Results From a Real-World Database.","authors":"Lee Quiruz, Negin Yavari, Bijal Kikani, Ankur Sudhir Gupta, Karen Michelle Wai, Andrea Lora Kossler, Chase Ludwig, Eubee Baughn Koo, Ehsan Rahimy, Prithvi Mruthyunjaya","doi":"10.1016/j.ajo.2024.11.001","DOIUrl":"10.1016/j.ajo.2024.11.001","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Scleral Thickness in Simple Versus Complex Central Serous Chorioretinopathy\".","authors":"Okihiro Nishi, Tsutomu Yasukawa","doi":"10.1016/j.ajo.2024.09.039","DOIUrl":"10.1016/j.ajo.2024.09.039","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142611950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Home OCT and Sustained Delivery Approaches, a Perfect Marriage: Home OCT and Sustained Drug Delivery: A Perfect Marriage.","authors":"Nancy M Holekamp","doi":"10.1016/j.ajo.2024.10.031","DOIUrl":"https://doi.org/10.1016/j.ajo.2024.10.031","url":null,"abstract":"<p><strong>Purpose: </strong>To provide a perspective on the management of neovascular age-related macular degeneration (nAMD) patients using a combination of sustained drug delivery strategies and remote monitoring technology.</p><p><strong>Design: </strong>Evidence-based perspective METHODS: Review of the literature and experience of the author RESULTS: Currently there are many ongoing research efforts in the retina field directed at both safe, effective sustained drug delivery and validated remote monitoring. At present, the Port Delivery System with ranibizumab and the Home OCT are FDA approved and available for use by clinicians. A review of available data and a case example demonstrate the potential for these combined technologies to reduce both the injection burden and the monitoring burden currently experienced by nAMD patients. Other sustained drug delivery strategies such as tyrorinse kinase inhibitor delivery systems and viral vector mediated anti-VEGF intraocular bio-factory models are not yet approved for clinical use. Early experience with these technologies in clinical trials foretell the potential advantages and possible limitations of remote monitoring with a variety of sustained delivery approaches.</p><p><strong>Conclusion: </strong>The combined use of sustained drug delivery and validated remote monitoring portends a significant change in the current nAMD treatment landscape and has the potential to reduce the injection and monitoring burden faced by patients while optimizing patient outcomes.</p>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do Ophthalmology Journals Have AI Policies for Manuscript Writing?","authors":"Amr Almobayed ,&nbsp;Taher K. Eleiwa ,&nbsp;Omar Badla ,&nbsp;Ali Khodor ,&nbsp;Raul E. Ruiz-Lozano ,&nbsp;Abdelrahman M. Elhusseiny","doi":"10.1016/j.ajo.2024.11.003","DOIUrl":"10.1016/j.ajo.2024.11.003","url":null,"abstract":"<div><h3>Purpose</h3><div>To assess the prevalence of artificial intelligence (AI) usage policies in manuscript writing in PubMed-indexed ophthalmology journals and examine the relationship between the adoption of these policies and journal characteristics.</div></div><div><h3>Design</h3><div>Cross-sectional study.</div></div><div><h3>Subjects</h3><div>PubMed-indexed ophthalmology journals.</div></div><div><h3>Main Outcome Measures</h3><div>Prevalence of policies in journal guidelines regarding the use of AI in manuscript writing.</div></div><div><h3>Methods</h3><div>We reviewed the guidelines of 84 ophthalmology journals indexed in PubMed to determine the presence of AI-use policies for manuscript generation. We further compared journal metrics, such as CiteScore, Journal Impact Factor (JIF), Journal Citation Indicator (JCI), Source Normalized Impact per Paper (SNIP), and SCImago Journal Rank (SJR), between journals with and without AI policies. Additionally, we analyzed the association between AI policy adoption and journal characteristics, such as MEDLINE indexing and society affiliation.</div></div><div><h3>Results</h3><div>Among the 84 journals, 53 (63.1%) had AI policies for manuscript generation, with no significant changes observed during the study period. Journals indexed in MEDLINE were significantly more likely to have AI policies (68.8%) than non-MEDLINE-indexed journals, where no AI policies were found (0%) (<em>P</em> = .0008). There was no significant difference in AI policy adoption between society-affiliated (62.7%) and unaffiliated journals (64.7%) (<em>P</em> = .84). Journals with AI policies had significantly higher metrics, including CiteScore, SNIP, SJR, JIF, and JCI (<em>P</em> &lt; .05).</div></div><div><h3>Conclusions</h3><div>While many ophthalmology journals have adopted AI policies, the lack of guidelines in over one-third of journals highlights a critical need for consistent and comprehensive AI policies, particularly as the AI landscape rapidly advances.</div></div>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"271 ","pages":"Pages 38-42"},"PeriodicalIF":4.1,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Circumferential Versus Hemi-gonioscopy-Assisted Transluminal Trabeculotomy for Congenital Glaucoma.","authors":"Shikha Gupta, Arnav Panigrahi, Anjana R, Anurag Kumar, Anand Kumar Pathak, Davinder S Grover, Viney Gupta","doi":"10.1016/j.ajo.2024.10.026","DOIUrl":"10.1016/j.ajo.2024.10.026","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the efficacy of circumferential gonioscopy-assisted transluminal trabeculotomy (GATT) vs hemi-GATT in primary congenital glaucoma (PCG).</p><p><strong>Design: </strong>Prospective randomized controlled trial.</p><p><strong>Methods: </strong>This study included children with PCG having corneal diameters <14 mm and relatively clear cornea. The eyes included were randomized to undergo either circumferential GATT (360-GATT) or hemi-GATT (180-GATT). The intraocular pressure (IOP) reduction, requirement for glaucoma medications after surgery, need for repeat surgery, and the incidence and type of complications in each group were analyzed. Surgical success was defined as absolute when IOP ≤18 mm Hg (criterion A) and ≤15 mm Hg (criterion B) was achieved without medications and qualified when the same was achieved with pressure-lowering medications. Eyes with an IOP ≥18 mm Hg on maximum medications, those with IOP <6 mm Hg, or need for further intervention for IOP control were considered failures.</p><p><strong>Results: </strong>Fifty-two eyes of children with PCG were randomized into either the 360-GATT group (22 eyes) or the 180-GATT group (30 eyes) and followed up for at least 1 year. The median follow-up duration was 22.5 months (range: 12-30 months). IOP fell by 49% and 20.5% with 360-GATT and 180-GATT, respectively, with the final IOP being significantly lower in the former group (P = .0003). For absolute success, the cumulative survival was superior with 360-GATT for both criterion A and B at 1 year (P = .009). Average cup-to-disc ratio, corneal diameter, and axial length reversal were significant in the 360-GATT group but not in the 180-GATT group.</p><p><strong>Conclusions: </strong>This study reinforces the superior efficacy of circumferential GATT for IOP control in eyes with congenital glaucoma.</p>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":" ","pages":"149-155"},"PeriodicalIF":4.1,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual Quality Following Femtosecond Laser-Assisted In Situ Keratomileusis With Q-Value-Guided Optimized Monovision in Patients With Myopia and Presbyopia.","authors":"Ruiyu Zhang, Yifei Yuan, Yu Zhang, Yueguo Chen","doi":"10.1016/j.ajo.2024.10.028","DOIUrl":"10.1016/j.ajo.2024.10.028","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the objective and subjective visual quality 3 months after femtosecond laser-assisted in situ keratomileusis (FS-LASIK) performed with Q-value-guided optimized monovision scheme (Custom-Q) for correction of myopia with or without astigmatism and compensate for age-related accommodation deficiency.</p><p><strong>Design: </strong>Prospective before-and-after study.</p><p><strong>Methods: </strong>Patients who had Custom-Q FS-LASIK for myopia with age-related accommodation deficiency were included in this prospective study. Distance, intermediate, and near visual acuities; refraction; Q value; corneal higher-order aberrations; accommodative and binocular function measurements; defocus curve; contrast sensitivity; and a subjective questionnaire assessing near visual ability and visual discomforts were evaluated before and after surgery.</p><p><strong>Results: </strong>Clinical data of 48 cases were analyzed. The mean age was 42.73 ± 2.67 years (range 40-50 years). At the 3-month follow-up, there were 100% (48/48), 92% (44/48), and 56% patients (27/48) who achieved a binocular uncorrected distance, intermediate, and near visual acuity not less than 20/20 separately. Defocus curves revealed better results postoperatively at -1.00 diopter (D) and -1.50 D. The Q value in the dominant eyes was more positive postoperatively (P < .001), and in the nondominant eyes, the Q value and corneal spherical aberration became more negative (P < .05). The accommodative amplitude and relative accommodation improved binocularly (P < .001). The questionnaire demonstrated high patient satisfaction with near vision, and patients' perceptions of visual discomforts had no significant difference compared with preoperative.</p><p><strong>Conclusion: </strong>For myopic patients with age-related accommodation deficiency, the Custom-Q ablation could improve near vision without compromising distance vision. It also led to minimal changes in objective optical quality, coordination of accommodative and binocular functions, contrast sensitivity, and subjective visual discomfort perceptions.</p>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":" ","pages":"156-165"},"PeriodicalIF":4.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes.","authors":"Kathleen Eng, Nazlee Zebardast, Michael V Boland, Jui-En Lo, Swarup S Swaminathan, David S Friedman, Kevin Sheng-Kai Ma","doi":"10.1016/j.ajo.2024.10.029","DOIUrl":"https://doi.org/10.1016/j.ajo.2024.10.029","url":null,"abstract":"<p><strong>Purpose: </strong>Pleiotropic cardiovascular benefits of sodium glucose co-transporter 2 inhibitors (SGLT2i) have been demonstrated in patients with type 2 diabetes mellitus due to vascular remodeling effects. It is unclear whether a similar benefit may be seen for glaucoma. The purpose of this study is to assess the effect of SGLT2i on the risk of glaucoma in patients with type 2 diabetes.</p><p><strong>Design: </strong>Target trial emulation using a population-based, propensity score-matched clinical cohort approach.</p><p><strong>Methods: </strong>Setting: Population-based, propensity score-matched clinical cohort study.</p><p><strong>Study population: </strong>Adults with type 2 diabetes in the United States who newly initiated treatment with SGLT2i, dipeptidyl peptidase 4 inhibitors (DPP4i), or glucagon-like peptide-1 receptor agonists (GLP1RA) between 2013 and 2023. After propensity score matching, 722,446 patients were included in the SGLT2i arm and the DPP4i arm, respectively. Participants were matched based on age at index, race and sex, comorbidities, and concomitant use of medications.</p><p><strong>Exposure: </strong>Treatment with SGLT2i for type 2 diabetes.</p><p><strong>Main outcome measure(s): </strong>Incidence of new-onset glaucoma and its subtypes after initiation of SGLT2i, DPP4i, or GLP1RA. Subgroup analyses were performed to demonstrate the effect of individual SGLT2i on incident glaucoma.</p><p><strong>Results: </strong>Patients on SGLT2i compared to those on DPP4 had a lower risk of glaucoma (HR: 0.815, 95% confidence interval [CI]: 0.794, 0.837), including open-angle glaucoma (HR: 0.755, 95%CI: 0.729, 0.781) and primary angle-closure glaucoma (HR: 0.592, 95%CI: 0.540, 0.650). Among all SGLT2i, ertugliflozin (HR: 0.668, 95%CI: 0.512, 0.871) was associated with the lowest risk of glaucoma, followed by empagliflozin (HR: 0.727, 95%CI: 0.696, 0.759), then dapagliflozin (HR: 0.814, 95%CI: 0.774, 0.855). The protective effect of SGLT2i on glaucoma was validated when compared with GLP1RA (HR: 0.932, 95%CI: 0.906, 0.959).</p><p><strong>Conclusions: </strong>Patients on SGLT2i, especially ertugliflozin and empagliflozin, had a significantly lower risk of incident glaucoma compared to those on DPP4i, an association that was less robust but significant in a sensitivity analysis using GLP1RA as the active comparator. SGLT2i had a protective effect for both open-angle glaucoma and angle-closure glaucoma.</p>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}